Corporate venture capital fund that invests in biotechs.
Profile being verified
What they look for
Co-led Nouscom's round with Revelation Partners; existing investor in FoRx Therapeutics. Hakan Goker, managing director and head of biotech investments, is quoted.
Recent investments
Recorded Swiss rounds: FoRx Therapeutics (Series A, USD 50 M, December 2025), Nouscom (Series C, USD 135 M, October 2026, co-lead).
Rounds tracked by FundSwiss
- NouscomSeries C and later · USD 135 M
- FoRx TherapeuticsSeries A · USD 50 M